A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery

Summary

This is phase II, single arm, open-label, interventional trial of pembrolizumab (MK-3475) in subjects with metastatic or locally advanced/unresectable or metastatic malignant peripheral nerve sheath tumour (MPNST). The patients will be treated with pembrolizumab for up to 10 cycles. Primary objective is to evaluate the percentage of patients with curatively unresectable MPNST who have achieved clinical response; complete response (CR), partial response (PR), or stable disease (SD) at 18 weeks as assessed by the Investigator, by using RECIST, v1.1.

Timeline

Start

2016-06

Primary completion

2020-12

Completion

2020-12

Outcome

Outcome not reported

Stopped (Enrollment): “Slow enrollment as a result of low incidence of MPNST and the COVID-19 pandemic.”

Drugs

Indications